A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (anti pdgf-b pegylated aptamer) administered in combination with either Avastin® or Eylea® compared to Avastin® or Eylea® monotherapy in subjects with sunfoveal neovascular age-related macular degeneration

HS 2014-1372
Eye, Macular Degeneration
Baruch Kuppermann, MD, PhD
The Gavin Herbert Eye Institute.
The goal of this study is to establish the safety and efficacy of intravitreous administration of Fovista™ (anti-PDGF-B pegylated aptamer) administered in combination with either Avastin® or Eylea® compared to Avastin® or Eylea® monotherapy in subjects with subfoveal neovascular age-related macular degeneration (AMD).
Males and females, 50 years of age or older at the screening visit, diagnosed with active subfoveal choroidal neovascularization (CNV) due to AMD.
Participation will include a total of 26 visits and will take about two hours of your time at each visit over the next 24 months.
Taking part in this study may or may not make a subject’s health better. While researchers hope the study drug will be more effective than the standard (usual) treatment, there is no proof of this yet. A subject’s condition may also get worse.
Subjects will receive $75 for each completed visit and may receive up to a total of $1950.00 for participation in this study.
Jeff Grijalva
714-456-7741